BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 15378491)

  • 1. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
    Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
    Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
    Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
    Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy.
    Hachem R; Gomes MZ; El Helou G; El Zakhem A; Kassis C; Ramos E; Jiang Y; Chaftari AM; Raad II
    J Antimicrob Chemother; 2014 Nov; 69(11):3148-55. PubMed ID: 25006241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi.
    Castón JJ; Linares MJ; Gallego C; Rivero A; Font P; Solís F; Casal M; Torre-Cisneros J
    Chest; 2007 Jan; 131(1):230-6. PubMed ID: 17218581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
    Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
    J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study.
    Rüping MJ; Gerlach S; Fischer G; Lass-Flörl C; Hellmich M; Vehreschild JJ; Cornely OA
    J Hosp Infect; 2011 Jul; 78(3):226-30. PubMed ID: 21440331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
    Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
    Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
    Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
    J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus.
    Torres HA; Rivero GA; Lewis RE; Hachem R; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2003 May; 46(1):25-8. PubMed ID: 12742315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive aspergillosis in a tertiary-care hospital in Thailand.
    Kiertiburanakul S; Thibbadee C; Santanirand P
    J Med Assoc Thai; 2007 May; 90(5):895-902. PubMed ID: 17596043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ; Seaton S; Prentice HG; Kibbler CC
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J; Rimek D; Kappe R
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
    Pastor FJ; Guarro J
    Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive interferon-γ immunotherapy in a pediatric case of Aspergillus terreus infection.
    Assendorp EL; Gresnigt MS; Sprenkeler EGG; Meis JF; Dors N; van der Linden JWM; Henriet SSV
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1915-1922. PubMed ID: 30027379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.